MA49726A - Formulation d'anticorps anti-cgrp - Google Patents
Formulation d'anticorps anti-cgrpInfo
- Publication number
- MA49726A MA49726A MA049726A MA49726A MA49726A MA 49726 A MA49726 A MA 49726A MA 049726 A MA049726 A MA 049726A MA 49726 A MA49726 A MA 49726A MA 49726 A MA49726 A MA 49726A
- Authority
- MA
- Morocco
- Prior art keywords
- formulation
- cgrp antibodies
- cgrp
- antibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562180905P | 2015-06-17 | 2015-06-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA49726A true MA49726A (fr) | 2020-06-10 |
Family
ID=56131672
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA049726A MA49726A (fr) | 2015-06-17 | 2016-06-08 | Formulation d'anticorps anti-cgrp |
Country Status (21)
Country | Link |
---|---|
US (3) | US11498959B2 (fr) |
EP (1) | EP3310809A1 (fr) |
JP (1) | JP6438599B2 (fr) |
KR (1) | KR102000867B1 (fr) |
CN (2) | CN107787229A (fr) |
AR (1) | AR104847A1 (fr) |
AU (1) | AU2016280555B2 (fr) |
BR (1) | BR112017023374A2 (fr) |
CA (1) | CA2984185A1 (fr) |
EA (1) | EA037580B1 (fr) |
HK (1) | HK1245813A1 (fr) |
IL (2) | IL292562A (fr) |
JO (1) | JO3772B1 (fr) |
MA (1) | MA49726A (fr) |
MX (1) | MX2017016199A (fr) |
MY (1) | MY184266A (fr) |
NZ (1) | NZ737046A (fr) |
TW (1) | TWI725973B (fr) |
UA (1) | UA120881C2 (fr) |
WO (1) | WO2016205037A1 (fr) |
ZA (1) | ZA201707324B (fr) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11951139B2 (en) | 2015-11-30 | 2024-04-09 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
US11951140B2 (en) | 2011-02-04 | 2024-04-09 | Seed Health, Inc. | Modulation of an individual's gut microbiome to address osteoporosis and bone disease |
US11844720B2 (en) | 2011-02-04 | 2023-12-19 | Seed Health, Inc. | Method and system to reduce the likelihood of dental caries and halitosis |
US11969445B2 (en) | 2013-12-20 | 2024-04-30 | Seed Health, Inc. | Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH |
US11833177B2 (en) | 2013-12-20 | 2023-12-05 | Seed Health, Inc. | Probiotic to enhance an individual's skin microbiome |
US11826388B2 (en) | 2013-12-20 | 2023-11-28 | Seed Health, Inc. | Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation |
US11980643B2 (en) | 2013-12-20 | 2024-05-14 | Seed Health, Inc. | Method and system to modify an individual's gut-brain axis to provide neurocognitive protection |
US11839632B2 (en) | 2013-12-20 | 2023-12-12 | Seed Health, Inc. | Topical application of CRISPR-modified bacteria to treat acne vulgaris |
US10556945B2 (en) | 2014-03-21 | 2020-02-11 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
JP6568099B2 (ja) | 2014-03-21 | 2019-08-28 | テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーTeva Pharmaceuticals International GmbH | カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体及びその使用方法 |
CA3037661A1 (fr) * | 2016-09-23 | 2018-03-29 | Teva Pharmaceuticals International Gmbh | Traitement de l'algie vasculaire de la face |
KR20220031944A (ko) | 2016-09-23 | 2022-03-14 | 테바 파마슈티컬스 인터내셔널 게엠베하 | 불응성 편두통의 치료 |
KR20190133174A (ko) | 2017-03-02 | 2019-12-02 | 베쓰 이스라엘 디코니스 메디칼 센터 인크 | 칼시토닌 유전자 관련 펩티드에 대해 지시되는 항체에 반응하는 두통 환자를 선택하는 방법 |
TWI754772B (zh) * | 2017-09-06 | 2022-02-11 | 美商美國禮來大藥廠 | 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法 |
US11407838B2 (en) * | 2018-04-02 | 2022-08-09 | Amgen Inc. | Erenumab compositions and uses thereof |
WO2019231800A1 (fr) * | 2018-05-31 | 2019-12-05 | Eli Lilly And Company | Anticorps anti-cgrp pour le traitement des migraines liées aux menstruations |
JP2022516956A (ja) | 2019-01-08 | 2022-03-03 | ハー・ルンドベック・アクチエゼルスカベット | 抗cgrp抗体を用いた頭痛の急性治療及び迅速治療 |
BR112020027063A2 (pt) * | 2019-05-02 | 2021-11-16 | H Lundbeck As | Tratamento de dor de cabeça com uso de anticorpos anti-cgrp |
US20240139171A1 (en) | 2021-03-02 | 2024-05-02 | Cgrp Diagnostics Gmbh | Treatment and/or reduction of occurrence of migraine |
WO2023026205A1 (fr) | 2021-08-24 | 2023-03-02 | Cgrp Diagnostics Gmbh | Traitement préventif de la migraine |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0627924T3 (da) | 1992-10-02 | 2001-04-30 | Genetics Inst | Sammensætning, der omfatter koagulationsfaktor VIII formulering, fremgangsmåde til dens fremstilling og anvendelse af et overfladeaktivt middel som stabilisator |
TWI240627B (en) | 1996-04-26 | 2005-10-01 | Chugai Pharmaceutical Co Ltd | Erythropoietin solution preparation |
ATE556591T1 (de) * | 2001-11-08 | 2012-05-15 | Abbott Biotherapeutics Corp | Stabile pharmazeutische flüssigformulierung von igg-antikörpern |
DK2236154T3 (en) | 2003-02-10 | 2018-06-25 | Biogen Ma Inc | IMMUNOGLOBULIN INFORMATION AND METHOD OF PREPARING IT |
JP2008528638A (ja) | 2005-01-28 | 2008-07-31 | ワイス | ポリペプチドの安定化液体処方 |
GT200600031A (es) | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
US20090110681A1 (en) | 2005-03-08 | 2009-04-30 | Pfizer, Inc. | Anti-M-CSF Antibody Compositions |
US9168286B2 (en) * | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
KR20140077946A (ko) * | 2005-10-13 | 2014-06-24 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물 |
BRPI0618705B8 (pt) * | 2005-11-14 | 2021-05-25 | Labrys Biologics Inc | anticorpos antagonistas humanizados direcionados contra peptídeo relacionado ao gene da calcitonina, composição farmacêutica e uso dos mesmos |
WO2007123765A2 (fr) | 2006-03-31 | 2007-11-01 | Human Genome Sciences Inc. | NEUTROKINE-ALPHA et variant d'epissage de la neutrokine-alpha |
AU2007331712A1 (en) * | 2006-12-11 | 2008-06-19 | F. Hoffmann-La Roche Ag | Abeta antibody parenteral formulation |
CN101600457B (zh) * | 2007-01-09 | 2014-01-08 | 惠氏公司 | 抗il-13抗体调配物和其用途 |
BRPI0809112A2 (pt) * | 2007-03-22 | 2014-08-26 | Imclone Llc | Formulações estáveis de anticorpos |
AU2008232902B2 (en) | 2007-03-30 | 2013-10-03 | Medlmmune, Llc | Antibody formulation |
CA2684323A1 (fr) * | 2007-04-18 | 2008-10-30 | Janssen Alzheimer Immunotherapy | Prevention et traitement d'angiopathie amyloide cerebrale |
CN102159204B (zh) * | 2008-09-19 | 2015-04-01 | 辉瑞公司 | 稳定的液体抗体制剂 |
EP3011953A1 (fr) | 2008-10-29 | 2016-04-27 | Ablynx N.V. | Formulations stabilisées de molécules de liaison d'antigène monodomaines |
EP2358392B1 (fr) * | 2008-11-12 | 2019-01-09 | MedImmune, LLC | Formulation d'anticorps |
CN104398471A (zh) * | 2008-11-28 | 2015-03-11 | Abbvie公司 | 稳定的抗体组合物和用于稳定其的方法 |
EP2196476A1 (fr) | 2008-12-10 | 2010-06-16 | Novartis Ag | Formulation d'anticorps |
RU2011140486A (ru) * | 2009-03-06 | 2013-04-20 | МЕДИММЬЮН, ЭлЭлСи | Композиции, содержащие гуманизированные антитела к cd19 |
JO3417B1 (ar) * | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
JO3330B1 (ar) * | 2010-06-10 | 2019-03-13 | Lilly Co Eli | الأجسام المضادة cgrp |
EP3831406B1 (fr) * | 2010-08-23 | 2024-06-05 | Wyeth LLC | Formulations stables des antigènes rlp2086 de neisseria meningitidis |
KR102031020B1 (ko) * | 2011-03-31 | 2019-10-14 | 머크 샤프 앤드 돔 코포레이션 | 인간 프로그램화된 사멸 수용체 pd-1에 대한 항체의 안정한 제제 및 관련된 치료 |
EA201891284A1 (ru) * | 2011-05-20 | 2018-11-30 | Олдербайо Холдингз Ллк | Композиции антител против cgrp и их применение |
CN104093739A (zh) | 2011-10-24 | 2014-10-08 | 艾伯维公司 | 针对tnf的免疫结合剂 |
WO2014031718A1 (fr) * | 2012-08-23 | 2014-02-27 | Merck Sharp & Dohme Corp. | Formulations stables d'anticorps contre la tslp |
JP2016505633A (ja) * | 2013-01-24 | 2016-02-25 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | TNFα抗原結合性タンパク質 |
JP6568099B2 (ja) * | 2014-03-21 | 2019-08-28 | テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーTeva Pharmaceuticals International GmbH | カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体及びその使用方法 |
-
2016
- 2016-06-01 AR ARP160101603A patent/AR104847A1/es unknown
- 2016-06-02 TW TW105117447A patent/TWI725973B/zh active
- 2016-06-05 JO JOP/2016/0111A patent/JO3772B1/ar active
- 2016-06-08 CA CA2984185A patent/CA2984185A1/fr active Pending
- 2016-06-08 CN CN201680034297.0A patent/CN107787229A/zh active Pending
- 2016-06-08 EA EA201792359A patent/EA037580B1/ru not_active IP Right Cessation
- 2016-06-08 KR KR1020177035870A patent/KR102000867B1/ko active Protection Beyond IP Right Term
- 2016-06-08 MA MA049726A patent/MA49726A/fr unknown
- 2016-06-08 UA UAA201712093A patent/UA120881C2/uk unknown
- 2016-06-08 NZ NZ73704616A patent/NZ737046A/en unknown
- 2016-06-08 BR BR112017023374-6A patent/BR112017023374A2/pt active Search and Examination
- 2016-06-08 CN CN202210229605.2A patent/CN114948847A/zh active Pending
- 2016-06-08 US US15/578,263 patent/US11498959B2/en active Active
- 2016-06-08 EP EP16729483.4A patent/EP3310809A1/fr active Pending
- 2016-06-08 JP JP2017564734A patent/JP6438599B2/ja active Active
- 2016-06-08 MY MYPI2017704814A patent/MY184266A/en unknown
- 2016-06-08 AU AU2016280555A patent/AU2016280555B2/en active Active
- 2016-06-08 IL IL292562A patent/IL292562A/en unknown
- 2016-06-08 MX MX2017016199A patent/MX2017016199A/es unknown
- 2016-06-08 WO PCT/US2016/036407 patent/WO2016205037A1/fr active Application Filing
-
2017
- 2017-10-27 ZA ZA2017/07324A patent/ZA201707324B/en unknown
- 2017-11-05 IL IL255443A patent/IL255443B/en unknown
-
2018
- 2018-04-26 HK HK18105442.3A patent/HK1245813A1/zh unknown
-
2021
- 2021-12-17 US US17/554,713 patent/US20220112277A1/en active Pending
-
2022
- 2022-08-08 US US17/883,072 patent/US20230159628A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
IL292562A (en) | 2022-06-01 |
IL255443B (en) | 2022-06-01 |
ZA201707324B (en) | 2020-01-29 |
US20180134772A1 (en) | 2018-05-17 |
MX2017016199A (es) | 2018-03-01 |
EP3310809A1 (fr) | 2018-04-25 |
JP2018517727A (ja) | 2018-07-05 |
KR20180002858A (ko) | 2018-01-08 |
AR104847A1 (es) | 2017-08-16 |
JP6438599B2 (ja) | 2018-12-19 |
EA201792359A1 (ru) | 2018-05-31 |
US11498959B2 (en) | 2022-11-15 |
CN114948847A (zh) | 2022-08-30 |
UA120881C2 (uk) | 2020-02-25 |
KR102000867B1 (ko) | 2019-07-16 |
JO3772B1 (ar) | 2021-01-31 |
CA2984185A1 (fr) | 2016-12-22 |
NZ737046A (en) | 2019-09-27 |
HK1245813A1 (zh) | 2018-08-31 |
AU2016280555A1 (en) | 2017-11-16 |
WO2016205037A1 (fr) | 2016-12-22 |
AU2016280555B2 (en) | 2018-11-15 |
CN107787229A (zh) | 2018-03-09 |
MY184266A (en) | 2021-03-30 |
TWI725973B (zh) | 2021-05-01 |
TW201711697A (zh) | 2017-04-01 |
US20220112277A1 (en) | 2022-04-14 |
US20230159628A1 (en) | 2023-05-25 |
EA037580B1 (ru) | 2021-04-16 |
IL255443A0 (en) | 2017-12-31 |
BR112017023374A2 (pt) | 2018-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA49726A (fr) | Formulation d'anticorps anti-cgrp | |
MA46525A (fr) | Anticorps anti-lag-3 et compositions | |
MA42924A (fr) | Variants optimisés d'anticorps anti-vegf | |
MA44659A (fr) | Anticorps anti-tim-3 et compositions | |
MA47694A (fr) | Anticorps anti-tigit | |
MA49034A (fr) | Anticorps anti-lag3 | |
MA49043A (fr) | Formulation stable d'anticorps | |
MA42925A (fr) | Anticorps anti-tigit et méthodes d'utilisation | |
MA45004A (fr) | Anticorps spécifiques anti-wt1-hla | |
MA47268A (fr) | Anticorps anti-gpc3 | |
MA53434A (fr) | Anticorps anti-tigit | |
KR20180084817A (ko) | 항-siglec-9 항체 및 이의 이용 방법 | |
MA53297A (fr) | Anticorps anti-icos | |
MA46057A (fr) | Anticorps anti-ctla4 | |
MA52884A (fr) | Anticorps anti-il-11 | |
MA42626A (fr) | Nouveaux anticorps anti-pd-1 | |
MA44381A (fr) | Format d'anticorps hétérodimères multispécifiques | |
MA42043A (fr) | Anticorps anti-ox40 et procédés d'utilisation de ceux-ci | |
MA43019A (fr) | Anticorps anti-humain cd19 à affinité élevée | |
MA47472A (fr) | Anticorps | |
MA51552A (fr) | Anticorps anti-ox40 et procédés d'utilisation | |
MA50352A (fr) | Anticorps multispécifiques | |
MA46180A (fr) | Analogues de l'amyline | |
MA44054A (fr) | Plateforme d'anticorps bispécifique | |
MA42843A (fr) | Anticorps anti-cd115 |